Young Houston Emergency Opioid Engagement System

Summary

The Houston Emergency Response Opioid Engagement System for Youths and Adolescents (Young HEROES) is a community-based research program integrating assertive outreach, medication for opioid use disorder (MOUD), behavioral counseling, and peer recovery support. The objective is to compare differences in engagement and retention in treatment for individuals with opioid use disorder. The investigators also intend to understand the prevalence of opioid overdoses and OUD among youth in Houston.

Conditions

• Opioid-use Disorder
• Opioid Dependence
• Opioid Overdose
• Opioid Use
• Substance Use Disorders

Interventions

DRUG

Buprenorphine, Naloxone Drug Combination

8mg of buprenorphine/2mg of naloxone to initiate MOUD treatment and bridge, if necessary, until referral to MOUD clinic can be made for ongoing treatment

BEHAVIORAL

Individual Counseling

One-on-one counseling with a licensed chemical dependency counselor

BEHAVIORAL

Peer Recovery Support Services

24/7 support from our team of certified peer recovery support specialists to assist with emotional support and case management

BEHAVIORAL

Support Group

Referrals to youth-focused support groups and eventual creation of in-house youth-focused support groups

BEHAVIORAL

Referral to Medication Management

Study staff will refer patients to long-term MOUD providers in the community

BEHAVIORAL

Assertive Outreach

The investigators will conduct weekly outreach to youths who experienced an opioid overdose and attempt to initiate treatment. Outreach is completed by a paramedic and peer coach.

Sponsors & Collaborators

• The University of Texas Health Science Center, Houston

  lead OTHER

Principal Investigators

• James R Langabeer, PhD · The University of Texas Health Science Center, Houston

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

13 Years

Max Age

17 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-19

Primary Completion

2030-08-31

Completion

2030-08-31

FDA Drug

Yes

Countries

• United States

Study Locations